Drugs / 5-(4-((2S,5S)-5-(4-CHLOROBENZYL)-2-METHYLMORPHOLINO)PIPERIDIN-1-YL)-1H-1,2,4-TRIAZOL-3-AMINE
5-(4-((2S,5S)-5-(4-CHLOROBENZYL)-2-METHYLMORPHOLINO)PIPERIDIN-1-YL)-1H-1,2,4-TRIAZOL-3-AMINE
Small molecule targets CHIT1 via inhibition
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05030857 | Sep → Nov 2021 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT04971746 | Jul 2021 → May 2022 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06205121 | Mar 2024 → Aug 2027 expected | pulmonary sarcoidosis | Molecure S.A. | Recruiting | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 5-(4-((2S,5S)-5-(4-CHLOROBENZYL)-2-METHYLMORPHOLINO)PIPERIDIN-1-YL)-1H-1,2,4-TRIAZOL-3-AMINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4788866 ↗ |
| Known as | GLP 4716 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4788866 ↗ |
| Known as | GLPG4716 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05030857 ↗ |
| Known as | OAT 889 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4788866 ↗ |
| Known as | OATD-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06205121 ↗ |
| Action | Inhibit | “OATD-01 is an oral inhibitor of chitinase-1 (CHIT1)” NCT06205121 ↗ |
| Modality | Small molecule | — CHEMBL4788866 ↗ |
| Route | Oral | “participants will receive GLPG4716 tablets once daily in fasted state” NCT05030857 ↗ |
| Target | CHIT1 | “inhibitor of chitinase-1 (CHIT1)” NCT06205121 ↗ |